-
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both encouraging news and a...
IN THE SPOTLIGHT
-
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools... -
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000... -
ALK Virtual Meetup
ALK patients/survivors - Join us the 4th Wednesday of every month to connect with others who share common experiences and build your community. -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects... -
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum... -
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung... -
6 Tips for Managing Scanxiety
Read time: 4 minutes. Scanxiety is a term used for the anxiety someone feels as a medical exam, like an MRI or CT scan, approaches. It can come with feelings of dread or worry, as... -
Why Do Some People Who Have Never Smoked Get Lung Cancer?
As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming...
EGFR vs. ALK: How molecular profiling defines lung cancer treatment
Conference Insights: Breaking Developments in ALK-Positive NSCLC and ES-SCLC Authors: Solange Peters, MD, PhD; Shirish M. Gadgeel, MD; Rafal Dziadziuszko, MD, PhD
Conference Insights: Breaking Developments in ALK-Positive NSCLC and ES-SCLC Authors: Solange Peters, MD, PhD; Shirish M. Gadgeel, MD; Rafal Dziadziuszko, MD, PhD
Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity
Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity
Next generation sequencing guided treatment of ALK tyrosine kinase inhibitor induced long survival in lung squamous cell carcinoma harboring ROS1 gene fusions: a case report and literature review
Next generation sequencing guided treatment of ALK tyrosine kinase inhibitor induced long survival in lung squamous cell carcinoma harboring ROS1 gene fusions: a case report and literature review
Pfizer QI Grants for ALK-Positive Lung Cancer (Spain)
Ensartinib targeted conversion surgery for ALK-positive unresectable locally advanced non-small cell lung cancer: a case report
Ensartinib targeted conversion surgery for ALK-positive unresectable locally advanced non-small cell lung cancer: a case report
From Metabolic to Pathologic Complete Response: Case Report of Neoadjuvant Lorlatinib in Stage IIIB ALK-Positive NSCLC Combined with Uniportal VATS
From Metabolic to Pathologic Complete Response: Case Report of Neoadjuvant Lorlatinib in Stage IIIB ALK-Positive NSCLC Combined with Uniportal VATS
Clinical Trial: Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
Clinical Trial: Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report
First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report